Claims
- 1. A lens implant, comprising a lens implant and a conjugate, said conjugate comprising a cytotoxic agent and a polypeptide reactive with a fibroblast growth factor receptor, wherein the conjugate is provided on the surface of the lens.
- 2. The implant of claim 1 that is coated with heparin prior to adsorption of the conjugate.
- 3. A composition formulated for use in inhibiting proliferation of epithelial lens cells in the eye of a patient, comprising an effective amount of a cytotoxic conjugate, wherein:
- the cytotoxic conjugate comprises a cytotoxic agent and a polypeptide reactive with a fibroblast growth factor receptor;
- the composition is formulated for local application to a posterior lens capsule; and
- the amount is effective for inhibiting proliferation of epithelial lens cells in the eye and preventing opacification of the posterior lens capsule following extracapsular cataract surgery.
- 4. The composition of claim 3, further comprising a product carrying polyanion charges for stabilizing the conjugate.
- 5. The composition of claim 3 or 4, wherein the effective amount is a concentration of the conjugate from 50 to 1000 nM in a volume of from 50 to 200 .mu.l.
- 6. The composition of claim 5, wherein the concentration provides a dosage of the cytotoxic conjugate of from 100 to 500 nM in a volume of from 50 to 200 .mu.l.
- 7. A method of inhibiting proliferation of epithelial lens cells, comprising, inserting a lens implant into an empty lens capsule of a patient, wherein a conjugate comprising a cytotoxic agent and a polypeptide reactive with a fibroblast growth factor (FGF) receptor is provided on a surface of the lens implant, and wherein the conjugate inhibits the proliferation of epithelial lens cells.
- 8. The method of claim 7, wherein the FGF is basic FGF and the cytotoxic agent is saporin.
- 9. The method of claim 7, wherein the polypeptide reactive with a FGF receptor is an FGF.
- 10. The method of claim 9, wherein the FGF is basic FGF.
- 11. The method of claim 7, wherein the cytotoxic agent is a ribosome-inactivating protein.
- 12. The method of claim 11, wherein the ribosome-inactivating protein is a type 1 ribosome-inactivating protein.
- 13. The method of claim 12, wherein the type 1 ribosome-inactivating protein is saporin.
- 14. A method of treating secondary lens clouding following extracapsular cataract surgery comprising, administering a lens implant to the eye of a patient, wherein a conjugate comprising a cytotoxic agent and a polypeptide reactive with a fibroblast growth factor (FGF) receptor is provided on a surface of the lens implant, and wherein the conjugate prevents secondary lens clouding.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9203533 |
Feb 1992 |
GBX |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 08/290,788, filed Oct. 12, 1994, now U.S. Pat. No. 5,843,893; which was filed under 35 U.S.C. Title 35, .sctn.371 from PCT Application No. PCT/EP93/00389, filed Feb. 18, 1993; which was based on Great Britain Application No. 9203533.6, filed Feb. 19, 1992.
This invention relates to uses of a conjugate comprising a cytotoxic agent and a polypeptide reactive with a fibroblast growth factor (FGF) receptor.
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9012597 |
Nov 1990 |
WOX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
290788 |
|
|